Browsing Tag
Jack Zhang
3 posts
Airwallex crossed $1bn in annualised revenue, so why is it still holding back from public markets?
Airwallex says it will be IPO-ready by year-end but sees little reason to rush into public markets. With annualised revenue above $1 billion, an $11 billion valuation and fresh expansion into autonomous finance, the bigger question is whether waiting strengthens the eventual listing or allows private-market expectations to run ahead of financial disclosure.
Lilly to sell hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals
Eli Lilly and Company (Lilly) has agreed to sell its severe hypoglycemia drug BAQSIMI to Amphastar Pharmaceuticals in…
Fintech platform Airwallex raises $100m funding at $5.5bn valuation
Airwallex has raised $100m in a Series E extension funding round that valued the Australian fintech company at…